ClinicalTrials.gg
CompletedNCT06949852Updated Jun 25, 2026

Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine for Postoperative Analgesia

A Phase 3 interventional study of Nalbuphine Hydrochloride Injection and Morphine Hydrochloride Injection in Postoperative Analgesia, sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd. Completed at 24 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Aug 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
289
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled intravenous analgesia (PCIA) for the treatment of postoperative analgesia

02

Conditions studied

  • Postoperative Analgesia
03

In context

Lead sponsor

Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years (inclusive), regardless of gender.
  2. Weight 45-100 kg (inclusive) and 18.0-30.0 kg/m² (inclusive).
  3. Preoperative ASA Physical Status Class I-III.
  4. Scheduled for elective general anesthesia in abdominal surgery (single incision ≥5 cm) or orthopedic surgery (limb/joint procedures); completed anesthesia recovery within 4 hours postoperatively, with NRS score ≥4, and willingness to accept protocol-defined analgesia.
  5. Ability to comprehend study objectives, operate PCIA devices, and communicate effectively with investigators.
  6. Female subjects must be non-pregnant, non-lactating, and agree to use (including partners) for 3 months post-study.
  7. Voluntary participation with signed .

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected allergy/ to any component of the product, other opioids, or drugs specified in the protocol .
  2. Neurological/psychiatric disorders including:

    1. neurological diseases (e.g., epilepsy, cognitive impairment) .
    2. History of brain injury, increased intracranial pressure, or psychiatric disorders (e.g., schizophrenia, bipolar disorder, depression, anxiety) that may interfere with safety or study assessments as judged by the investigator .
  3. Cardiovascular diseases/history:

    1. Severe cardiovascular conditions ( Class II or higher), myocardial infarction, angina, or severe arrhythmia within the past year .
    2. Abnormal 12-lead findings during screening (e.g., sinus bradycardia ≤55 bpm, ≥Grade II AV block) deemed unsuitable by the investigator .
    3. Resting systolic blood pressure ≥160 mmHg or \<90 mmHg, diastolic ≥100 mmHg pre-surgery .
    4. Intraoperative circulatory instability (e.g., hypotension, bradycardia) assessed as high-risk for trial continuation .
  4. Respiratory disorders/history:

    1. Bronchial asthma, high-risk respiratory depression conditions (e.g., severe ≥GOLD 3, sleep apnea syndrome) .
    2. Preoperative SpO2 \<93% (room air) or intraoperative respiratory depression/ventilatory dysfunction deemed unsafe .
  5. Paralytic ileus, biliary/pancreatic diseases within 12 months before screening .
  6. Major surgery within 3 months prior to screening.
  7. Acute/chronic non-surgical pain interfering with postoperative pain assessment .
  8. Preoperative anemia: \<70 g/L or hematocrit \<25% .
  9. High bleeding risk:

    1. Congenital bleeding disorders (e.g., hemophilia) .
    2. count \<0.75×LLN, PT >+3s, or >ULN+10s .
  10. Organ dysfunction:

    1. Albumin \<35 g/L (untreated) .
    2. Liver/kidney function abnormalities: //AST/ALP ≥1.5×ULN ; Creatinine ≥1.5×ULN or clinically significant renal impairment; Recent dialysis (within 28 days) .
  11. Random blood glucose ≥11.1 mmol/L during screening (preoperative) .
  12. Participation in other clinical trials with active treatment within 3 months before surgery .
  13. Other conditions deemed unsuitable by the investigator for safety or protocol compliance.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
289 participants (actual)

Study arms

  • Experimental
    Nalbuphine group

    Drug: Nalbuphine Hydrochloride Injection

  • Active comparator
    Morphine group

    Drug: Morphine Hydrochloride Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Sum of Pain Intensity Difference over 0-48 hours(SPID48)

    SPID48=∑PID48×\[time in hours slapsed since the previous observation\], PID48 denotes the pain intensity difference at time 48 hours after the first administration relative to baseline. The pain intensity is rated using an 11-point numeric scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable."

    Time frame: 0-48 hours

Secondary outcomes

  1. Sum of Pain Intensity Difference over 0-12 hours(SPID12)

    SPID12=∑PID12×\[time in hours slapsed since the previous observation\], PID12 denotes the pain intensity difference at time 12 hours after the first administration relative to baseline. The pain intensity is rated using an 11-point numeric scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable."

    Time frame: 0-12 hours

  2. Sum of Pain Intensity Difference over 0-24 hours(SPID24)

    SPID24=∑PID24×\[time in hours slapsed since the previous observation\], PID24 denotes the pain intensity difference at time 24 hours after the first administration relative to baseline. The pain intensity is rated using an 11-point numeric scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable."

    Time frame: 0-24 hours

  3. Sum of Pain Intensity Difference over 0-32 hours(SPID32)

    SPID32=∑PID32×\[time in hours slapsed since the previous observation\], PID32 denotes the pain intensity difference at time 32 hours after the first administration relative to baseline. The pain intensity is rated using an 11-point numeric scale ranging from 0 to 10, where 0 represents "no pain" and 10 represents "the worst pain imaginable."

    Time frame: 0-32 hours

  4. Total Number of PCIA Pump attempts during 0~48h

    The PCIA protocol was implemented as follows: For subjects with baseline NRS scores ≥4, investigators administered the first PCIA bolus to initiate analgesia.The exact time of investigator's first PCIA activation was recorded as D0-0h. PCIA Pump Settings: Experimental Group: 2 mg per demand dose (2 mL/dose); Control Group: 1 mg per demand dose (2 mL/dose); Lockout Interval: 10 minutes. Background Infusion: None. Subsequent Analgesia Management: Following initial activation, subjects self-administered additional PCIA doses as needed based on pain levels. Subsequent PCIA Use: Subjects self-administer additional PCIA doses as needed based on pain levels. PCIA Discontinuation \& Data Collection: At 48 hours (±20 min) after the first study drug administration (or upon early withdrawal), study staff will: pause and disconnect the PCIA pump, Record: total number of PCIA presses, number of effective presses and total dosage of study drug delivered via PCIA

    Time frame: 0-48 hours

  5. Number of Effective Deliveries during 0~48h

    The PCIA protocol was implemented as follows: For subjects with baseline NRS scores ≥4, investigators administered the first PCIA bolus to initiate analgesia.The exact time of investigator's first PCIA activation was recorded as D0-0h. PCIA Pump Settings: Experimental Group: 2 mg per demand dose (2 mL/dose); Control Group: 1 mg per demand dose (2 mL/dose); Lockout Interval: 10 minutes. Background Infusion: None. Subsequent Analgesia Management: Following initial activation, subjects self-administered additional PCIA doses as needed based on pain levels. Subsequent PCIA Use: Subjects self-administer additional PCIA doses as needed based on pain levels. PCIA Discontinuation \& Data Collection: At 48 hours (±20 min) after the first study drug administration (or upon early withdrawal), study staff will: pause and disconnect the PCIA pump, Record: total number of PCIA presses, number of effective presses and total dosage of study drug delivered via PCIA

    Time frame: 0-48 hours

  6. Total Delivered Dose during 0~48h

    The PCIA protocol was implemented as follows: For subjects with baseline NRS scores ≥4, investigators administered the first PCIA bolus to initiate analgesia.The exact time of investigator's first PCIA activation was recorded as D0-0h. PCIA Pump Settings: Experimental Group: 2 mg per demand dose (2 mL/dose); Control Group: 1 mg per demand dose (2 mL/dose); Lockout Interval: 10 minutes. Background Infusion: None. Subsequent Analgesia Management: Following initial activation, subjects self-administered additional PCIA doses as needed based on pain levels. Subsequent PCIA Use: Subjects self-administer additional PCIA doses as needed based on pain levels. PCIA Discontinuation \& Data Collection: At 48 hours (±20 min) after the first study drug administration (or upon early withdrawal), study staff will: pause and disconnect the PCIA pump, Record: total number of PCIA presses, number of effective presses and total dosage of study drug delivered via PCIA

    Time frame: 0-48 hours

  7. Time to First Use of Rescue Medication

    Time to first use of rescue medication during 0\~48h.(For subjects with inadequate pain control (NRS score ≥4) who consent to rescue therapy, the following conditions must be met before administering rescue medication: 1) NRS score remains ≥4 within 5 minutes prior to rescue drug administration; 2) At least 5 minutes have elapsed since the last effective PCIA pump press, and the next PCIA bolus is not yet due)

    Time frame: 0-48 hours

  8. Proportion of Subjects Requiring Rescue Medication

    Time frame: 0-48 hours

  9. Number of Rescue Medication Administrations

    Time frame: 0-48 hours

  10. Proportion of Subjects with Treatment Failure

    Time frame: 0-48 hours

  11. Patient Global Impression of Change (PGIC) at 48 Hours Post-Dose

    The PGIC scale (6-point) will be administered at 48h (±30min) post-dose to evaluate patients' perceived change in analgesia, ranging from 'Very much improved' (1) to 'Much worse' (6).

    Time frame: 0-48 hours

07

Study locations

24 sites
  • Peking University First Hospital
    Beijing, China
  • Cangzhou People's Hospital
    Cangzhou, China
  • The First People's Hospital of Changde City
    Changde, China
  • The Third Xiangya Hospital of Central South Univerdity
    Changsha, China
  • Heping Hospital affiliated to Changzhi Medical College
    Changzhi, China
  • Chengdu Fifth People's Hospital
    Chengdu, China
  • Sichuan Provincial People's Hospital
    Chengdu, China
  • Chongqing University Affiliated Fuling Central Hospital
    Chongqing, China
  • Deyang People's Hospital
    Deyang, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, China
  • The First Affiliated Hospital of Jinan University
    Guangzhou, China
  • The First Affiliated Hospital Of University Of South China
    Hengyang, China
  • The Second Affiliated Hospital of Jiaxing University
    Jiaxing, China
  • The First People's Hospital of Lianyungang
    Lianyungang, China
  • Liuzhou Worker's Hospital
    Liuzhou, China
  • Mianyang Central Hospital
    Mianyang, China
  • Nanjing Drum Tower Hospital
    Nanjing, China
  • The Second Nanning People's Hospital
    Nanning, China
  • Ningbo Medical Center LIHUILI Hospital
    Ningbo, China
  • Ningbo NO.2 Hospital
    Ningbo, China
  • Shanxi Bethune Hospital
    Taiyuan, China
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, China
  • Affiliated Hospital of Jiangnan University
    Wuxi, China
  • Xi'an Honghui Hospital
    Xi'an, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Jul 2025, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 29, 2025
StartActual
Aug 7, 2024
Primary completionActual
Jul 8, 2025
CompletionActual
Aug 4, 2025
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06949852
Lead sponsor
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
Responsible party
Sponsor
First posted
Apr 29, 2025
Start date
Aug 7, 2024
Primary completion
Jul 8, 2025
Completion
Aug 4, 2025
Last update
Jun 25, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion